FDAnews
www.fdanews.com/articles/190193-fda-cites-novabay-for-design-control-procedures
FDA_Logo_Black_2016.gif

FDA Cites Novabay for Design Control Procedures

February 11, 2019

Novabay Pharmaceuticals, an Emeryville, California drug and device manufacturer, was hit with a Form 483 for faulty design control procedures.

The firm’s design control procedure described design validation as “optional,” and the company was unable to provide a documented design validation.

The procedure also said that reviews for transition and major designs are recorded on the design review report form — but the firm had no proof of a design review conducted before the product’s release to market.

View today's stories